Previous findings have provided strong evidence that myostatin functions as a negative regulator of muscle mass during development and growth. In the present study, we test the hypothesis that myostatin may serve a similar function in fully differentiated muscle experiencing modified loading. Our findings show that myostatin expression can be modulated in fully differentiated, nonpathological skeletal muscle in a manner that is inversely related to changes in muscle mass. Atrophy of rat hind limb muscles induced by 10 days of unloading resulted in a 16% decrease in plantaris mass, a 110% increase in myostatin mRNA, and a 37% increase in myostatin protein. Immunohistochemical observations showed a detectable increase in myostatin concentration at myotendinous junctions during muscle unloading. The concentration of myostatin mRNA and protein returned to values not significantly different from ambulatory controls after 4 days of reloading, during which time plantaris mass also returned to control values. However, the results also show that periods of 30 min of daily muscle loading during the unloading period were sufficient to prevent significant losses of muscle mass caused by unloading, although myostatin mRNA still showed a 55% increase in concentration. Thus, significant increases in myostatin expression are not sufficient for muscle mass loss, although muscle mass loss during unloading is accompanied by increases in myostatin.-Wehling, M., Cai, B., Tidball, J. G. Modulation of myostatin expression during modified muscle use. FASEB J. 14, 103-110 (2000)
Myostatin, a member of the transforming growth factor-␤ (TGF-␤) superfamily, is specifically expressed in skeletal muscle where it functions as a negative regulator of tissue growth. This function was first suggested by McPherron et al. (1) , who observed a twoto threefold increase in the muscle mass of myostatin knockout mice when compared to controls. Myostatin is transcribed as a 2.9 kb mRNA species and translated as disulfide-linked dimer that is subsequently secreted, processed, and thought to function in an autocrine and/or paracrine manner similar to that of other TGF-␤ superfamily proteins (1) .
The importance of myostatin as a regulator of skeletal muscle mass has been well established, first in myostatin null mutant mice and subsequently in Belgian Blue and Peidmontese cattle. The significantly increased muscle mass observed in Belgian Blue and Peidmontese cattle, known as the 'doublemuscled' phenotype, seems to be due to a lack of functional myostatin protein. The myostatin coding sequence of Belgian Blue cattle has an 11-nucleotide deletion, which ultimately results in expression of a truncated protein product; Peidmontese cattle also express a nonfunctional myostatin protein due to a missense mutation in the gene sequence (2) (3) (4) . Although the mechanism by which a lack of myostatin results in increased muscle mass is not known, myostatin null mutants exhibit both muscle hypertrophy and hyperplasia (1) .
A functional role for myostatin in fully differentiated muscle has not yet been established and current data present an unclear picture of what role the protein may play. The finding that HIV-positive men who experience severe muscle atrophy express higher levels of a serum and muscle protein with similar structure to myostatin (myostatin-immunoreactive protein) supports the possibility that myostatin may act as a negative regulator of muscle mass during pathological wasting of muscle (5) . However, the relationship between myostatin and myostatinimmunoreactive protein has not yet been established. Mouse muscles subjected to 1 day of hind limb muscle unloading showed a significant increase in myostatin mRNA concentration but no significant decrease in muscle mass, whereas muscle mass was significantly reduced after 3 and 7 days of unloading, although myostatin mRNA levels were not significantly elevated at those times (6) . Finally, suppression of muscle growth by 3 days of food deprivation did not affect the expression of myostatin message in piglets (7) . Thus, there is no simple relationship between changes in myostatin mRNA concentration and changes in muscle mass, and no information concerning changes in myostatin protein expression and modified muscle use.
In the present investigation, we test the hypothesis that modifications in muscle loading influence the expression and distribution of myostatin, and that changes in the expression of myostatin mRNA and protein relate inversely to changes in muscle mass. Three experimental perturbations are used to test the hypotheses. First, rat hind limb muscle unloading for a period of 10 days was used since previous investigations have shown that this treatment leads to rapid loss of mass of soleus and plantaris muscles (8) . Second, 10 days of hind limb unloading, followed by 4 days of reloading by return to normal weightbearing, was used to produce a period of rapid increase in muscle mass. Finally, 10 days of unloading during which rats are subjected to daily periods of 30 min of muscle loading was used. The latter treatment was chosen because it subjects hind limb muscles to dramatically different patterns of loading, with little or no change in muscle mass (9 -11) . This will enable us to determine whether changes in myostatin expression relate to modifications in muscle loading or modifications in muscle mass.
MATERIALS AND METHODS

Animals
Female Wistar rats (260 -280 g) were purchased from Harlen Sprague Dawley (Indianapolis, Ind.) and subsequently housed at the UCLA vivarium prior to and during experimental perturbations. Rats were killed by intraperitoneal injection of sodium pentobarbital (100 mg/kg). Immediately after killing of animals, tissues were isolated and stored for subsequent use. Tissues to be used for Western or Northern analysis were stored in liquid nitrogen. Muscles for immunohistochemical analysis were frozen in liquid nitrogen-cooled isopentane and stored in isopentane-filled vials at Ϫ70°C.
Muscle unloading and loading procedures
Rats were subjected to hind limb unloading for 10 days by a modification of the protocol described by Morey-Holton and Wronski (8) according to procedures approved by the University of California, Los Angeles, Animal Research Committee. Four treatment groups were analyzed. The first group (nϭ15) consisted of ambulatory controls. Animals in the second group (nϭ15) were subjected to 10 days of unloading of the hind limb muscles, after which they were killed without experiencing muscle reloading. In the third group (nϭ9), rats were similarly subjected to hind limb muscle unloading for 10 days, but during this period they were also subjected to 30 min each day of loading the hind limb muscles by exercise on a treadmill at 5 m/min on a 20% grade. Rats in the last group (nϭ6) were removed from the hind limb unloading apparatus after 10 days of unloading and allowed to recover for 4 days with normal cage activity, when hind limb muscles experienced reloading.
Western analysis
Whole muscle extracts of tissues were prepared by homogenizing samples in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reducing buffer (80 mM TrisHCl pH 6.8, 0.1 M dithiothreitol, 70 mM SDS, 1.0 mM glycerol). Samples were boiled for 1 min, then centrifuged at 12,000 ϫ g for 1 min. The supernatant fraction of each sample was removed and used to determine protein concentration by measuring absorbance at 280 nm. Homogenates containing 50 g of total protein were separated on 12% SDS-PAGE gels according to Laemmli (12) . Proteins were electrophoretically transferred onto nitrocellulose membranes while immersed in transfer buffer (39 mM glycine, 48 mM Tris) (13) .
After transfer, membranes were blocked in buffer containing 0.5% Tween-20, 0.2% gelatin, and 3.0% dry milk (blocking buffer) for at least 1 h at room temperature. Membranes were probed with polyclonal anti-myostatin for 2 h at room temperature. Subsequently, membranes were overlaid with alkaline phosphatase-conjugated anti-rabbit IgG (Sigma, St. Louis, Mo.) for 1 h at room temperature. After each incubation, membranes were washed six times for 10 min in wash buffer (0.5% Tween-20, 0.2% gelatin, and 0.3% dry milk). Blots were developed using nitroblue tetrazolium and bromochloro-indolyl phosphate.
Relative concentration of myostatin protein in each sample was determined by scanning densitometry (Alpha Innotec, San Leandro, Calif.). Uniformity of protein loading and efficiency of transfer were assessed by staining membranes with Ponceau S (Sigma) after electrophoretic transfer.
Polyclonal anti-myostatin production
A sequence of 20 amino acids (aa #100 -119) from the portion of the myostatin protein sequence encoding the latent peptide, which is unique to myostatin, was chosen for antibody production based on its lack of homology to other known proteins. This 20 mer was synthesized by Research Genetics (Huntsville, Ala.) and subsequently conjugated to the carrier molecule, hemocyanin keyhole limpet (KLH) (Calbiochem, San Diego, Calif.). The peptide-KLH conjugate was emulsified in Freund's complete adjuvant and injected subcutaneously into a New Zealand White rabbit after collection of preimmune serum. The rabbit received a booster injection of the peptide-KLH conjugate emulsified in Freund's incomplete adjuvant each 4 wk and serum was collected from an ear vein 10 -14 days after each injection.
Northern analysis
RNA was isolated according to Chomczynski and Sacchi (14) . The final RNA pellets were resuspended in 10 -25 l of 10 mM Tris, pH 8.0 with 1 mM ethylene diamine tetraacetic acid (EDTA). The concentration of RNA in each sample was determined by measuring absorbance at 260 nm. Samples containing 5 g of total RNA were loaded onto 1.2% formaldehyde-agarose gels and electrophoresed overnight at 25 V. The RNA samples were electrophoretically transferred to uncharged nylon membranes, ultraviolet cross-linked with 150 mJ, and subsequently stained with methylene blue to verify uniformity of loading and efficiency of transfer.
Membranes were prehybridized in Denhardt's solution, 4ϫ SSC (0.03 M citric acid trisodium-0.3 sodium chloride), 1% SDS, and 100 g/ml herring sperm DNA for at least 1 h at 65°C. Membranes were hybridized in Denhardt's solution, 4ϫ SSC, 1% SDS, 100 g/ml herring sperm DNA, and 10% sodium dextran sulfate with 2 ϫ 10 6 cpm/ml of ␣-32 P-labeled myostatin cDNA probe (specific activity Ͼ 1ϫ10 8 cpm/l) overnight at 65°C. Membranes were washed six times for 20 min with 0.05 M sodium phosphate, 0.75 M sodium chloride, 5 mM EDTA, and 0.1% SDS and exposed to autoradiographic film for 1-5 days at Ϫ80°C.
Relative concentration of myostatin RNA in each sample was determined by scanning densitometry (Alpha Innotec). Uniformity of loading was verified by stripping blots and reprobing with pTRI RNA 18s control probe (Ambion Inc., Austin, Tex.).
Production of myostatin cDNA probe
After reverse transcriptase-polymerase chain reaction (RT-PCR) of total RNA isolated from C57 plantaris, the resulting cDNA was subjected to PCR with the upper primer 5Ј-GAGGGATGACAGCAGTGATGGCTCTTTGG-3Ј and the lower primer 5Ј-CGGTCTACTACCATGGCTGGAATTT-TCCC-3Ј, yielding a product of the expected size of 822 bp. PCR using these primers was carried out at 94°C for 45 s, 56°C for 1 min, and 72°C for 3 min for 35 cycles. The 822 bp product was cloned into the pCR 2.1 vector using the Original TA Cloning Kit (Invitrogen, San Diego, Calif.). After digestion with EcoRI, the cloned PCR product was sequenced (UCLA DNA Sequencing Facility, Los Angeles, Calif.) and confirmed to correspond to the cDNA sequence for mouse myostatin.
Immunohistochemical analysis
Ten micrometer-thick longitudinal sections were cut from rat muscles samples, transferred to microscope slides coated with 0.4% gelatin and 0.04% chromium potassium sulfate, and stored at Ϫ20°C. Prior to staining, slides were air dried for 30 min at room temperature. Sections were then fixed in icecold acetone for 10 min, air dried, and quenched in 0.3% hydrogen peroxide for 5 min. After fixation, sections were blocked in a buffer containing 0.05% Tween-20, 0.02% gelatin, and 3% bovine serum albumin. Sections were incubated either with or without polyclonal anti-myostatin overnight at 4°C. Sections were then incubated with biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, Calif.) and subsequently with horseradish peroxidase avidin-D (Vector Laboratories) for 30 min each. Slides were washed three times 5 min in phosphate-buffered saline after each incubation. Slides were developed using 3-amino-9-ethyl carbazole (AEC, red) as substrate.
A cross-sectional area of plantaris muscles was measured by counting the number of intercepts of vertical and horizontal lines in a square grid of an eyepiece micrometer that overlays muscle tissue when viewed with a 10ϫ objective. Each intercept of the grid corresponded to 0.33 M (2) when viewed at this magnification. All sections used for analysis were taken from the thickest portion of the belly of each plantaris muscle.
Statistical analysis
The significance of differences between experimental and control samples was determined using one-way analysis of variance, with the confidence limit set at PϽ0.05.
RESULTS
Assays for myostatin protein and mRNA expression
Northern analysis of mRNA isolated from soleus and plantaris muscles produced a single band at 2.9 kb, which is the expected size for myostatin mRNA (Fig.  1) . The concentration of myostatin mRNA was 17-fold greater in plantaris than in soleus (Fig. 2) . No myostatin mRNA was detected in nonmuscle tissues that were assayed (Fig. 1) .
Protein samples obtained from the same tissues analyzed in Northern blots were assayed in Western blots using polyclonal anti-myostatin (Fig. 3) . Antimyostatin recognized a single polypeptide in plantaris muscle at ϳ35 kDa and a single polypeptide in soleus muscle at ϳ37 kDa. As expected, these masses correspond to the size of the latent myostatin monomer in reduced form. Similar to the distribution pattern of myostatin mRNA, the concentration of myostatin protein was 2.5-fold greater in plantaris as compared to soleus. Because higher levels of myostatin mRNA and protein expression were observed in plantaris muscle, it was chosen for all subsequent analyses. No myostatin protein was detected in nonmuscle tissues that were assayed (Fig. 3) .
Myostatin expression is modulated during modified muscle use
The decrease in plantaris muscle wet mass that occurred during hind limb unloading (-16%) ( Table  1 ) was accompanied by changes in the levels of myostatin mRNA and myostatin protein concentrations (Figs. 4 -7) . The reduction of muscle crosssectional area during unloading (-28%) was more than sufficient to account for muscle mass loss during the unloading period and indicates that muscle shortening did not contribute substantially to the mass losses observed. The 10 day period of hind limb unloading resulted in a significant increase (ϩ110%) in myostatin mRNA concentration with a smaller, significant increase in myostatin protein levels (ϩ37%). Four days of reloading were sufficient to return plantaris mass (Table 1) and myostatin mRNA and protein concentrations (Figs. 4 -7) to values that were not statistically different from ambulatory controls.
Periodic loading during the period of hind limb suspension diminished or eliminated the changes in plantaris muscle mass and myostatin mRNA concentration that occurred during hind limb unloading. Those animals experiencing periodic loading showed no significant difference in plantaris muscle mass compared to ambulatory controls (Fig. 8) . The concentration of myostatin mRNA in the plantaris muscles of animals experiencing periodic loading was 55% greater than ambulatory controls and significantly less than the 110% increase that occurred in animals that experienced unloading for 10 days without periodic loading (Fig. 5 and Fig. 9 ).
Muscle unloading increases myostatin concentration at myotendinous junctions
Myostatin protein was found to be concentrated at the myotendinous junction (MTJ) in ambulatory control animals (Fig. 10A, B) . A similar distribution of myostatin protein was observed in tissue samples from animals subjected to hind limb unloading and/or reloading (Fig. 10D, E) . However, myostatin protein concentration at the MTJs of unloaded muscles was detectably greater than in ambulatory controls or animals experiencing reloading (Fig. 10G,  H) . Myostatin was not observed in periodic bands at the lateral surface of the fibers, called costameres, where proteins enriched at MTJs are frequently observed (15) .
DISCUSSION
The findings of the present investigation show that changes in muscle loading cause modifications in expression of myostatin mRNA and protein in fully differentiated muscle. The elevation of myostatin expression during muscle unloading and its decrease during reloading are consistent with previous interpretations of myostatin's function in developing systems that have demonstrated a negative influence of myostatin on muscle hypertrophy and hyperplasia (1) . Note that developmental events including satellite cell activation, formation of new myotubes, and renewed expression of genes that are normally expressed during development also occur with reloading (16), when myostatin expression decreases. This suggests that similar mechanisms may underlie myostatin's influence on muscle mass in developing and fully differentiated tissue.
Although the results presented here show that changes in muscle mass are accompanied by reciprocating changes in myostatin expression, the occurrence of significant elevations of myostatin expression during modified muscle loading is not sufficient to cause significant loss of muscle mass. This conclu- sion is supported by the finding that animals subjected to prolonged periods of muscle unloading with intermittent muscle loading experienced no significant loss of muscle mass, but showed significant increases in myostatin concentration. Thus, either the increase in myostatin expression that occurs in unloaded muscle subjected to intermittent loading is not sufficient to produce detectable mass loss or other variables override the potential regulatory influence of myostatin on muscle mass during modified muscle use.
Recent findings (5) showing that myostatin-immunoreactive protein is present at higher concentrations in the serum and muscle of HIV-infected men has suggested that myostatin may also play a role in the pathological wasting of muscle. However, the relationship between myostatin-immunoreactive protein and myostatin has not yet been established. The antibody recognizing myostatin-immunoreactive protein was generated against a peptide present in the mature or active domain of myostatin, and was shown to bind to 26 kDa polypeptide in immunoblots. However, SDS-PAGE under reducing conditions of murine myostatin expressed in CHO cells shows the active myostatin peptide migrates at a mass of ϳ15 kDa (1). It has been speculated that the mass discrepancy between myostatin and myostatin-immunoreactive protein may be due to differential processing and glycosylation of the human form of the protein (5). Alternatively, anti-myostatin immunoreactive protein may recognize a nonmyostatin protein. For example, the peptide used to generate anti-myostatin-immunoreactive protein is highly homologous to a sequence in mature GDF-11, another TGF-␤ superfamily protein (17) . Although the presence of GDF-11 in skeletal muscle has not yet been confirmed, it is expressed in a number of other tissues that may potentially secrete the protein into serum, thereby creating the possibility of cross-reactivity with anti-myostatin-immunoreactive protein.
The antibody used in the current study was generated against a unique peptide present in the precursor, or latent domain, of myostatin. Although it was anticipated that the antibody used in the present investigation would recognize both the latent domain of cleaved myostatin at 37 kDa and the intact precursor at 52 kDa, only a 37 kDa polypeptide was identified. This may indicate that the intact precursor is not present in the tissue or, more likely, that sample processing for Western analysis dissociated the intact complex. Dissociation of active and latent peptides of other members of the TGF-␤ superfamily by chaotrophic agents such as SDS has been demonstrated previously (18, 19) . We have been unable to confirm this speculation experimentally because the anti-myostatin used here appears to recognize the antigen only under denaturing and reducing conditions; it has not been used successfully for immunoprecipitation or affinity chromatographic isolation of either the latent or intact myostatin. Presumably, the binding of the antibody to myostatin in tissue sections occurs because acetone fixation and peroxide treatment denature the protein and thereby expose the epitope to which the antibody binds. The higher concentration of myostatin mRNA (ref 6; present investigation) and myostatin protein (present investigation) in fast-twitch muscle than in slow twitch muscle indicates that myostatin's function is likely to be more prominent in fast muscle. In addition, the present finding that the molecular mass of myostatin differs in plantaris and soleus muscles, suggests that there may be fiber type-specific, posttranslational modifications in myostatin that relate to fiber type-specific functions. Modifications in myostatin glycosylation may underlie the observed mass differences because glycosylation is a common posttranslational modification in TGF-␤ superfamily members (20, 21 ). An intriguing hypothesis put forward by Carlson et al. (6) that may relate to the elevated expression in fast-twitch muscles is that myostatin may function as an inhibitor of satellite cell proliferation. This speculation is supported by several previous observations that include 1) myostatin null mutants display muscle hypertrophy and hyperplasia (1), both of which may relate to elevated satellite cell activity, 2) hind limb unloading causes suppression of satellite cell proliferation (22) , which would coincide with increased myostatin expression, and 3) fast-twitch muscles have lower concentrations of satellite cells (23) , which would coincide with the higher level of expression of myostatin in fast muscle. If myostatin is found to function in regulating satellite cell proliferation and activity, the protein's elevated concentration at MTJs, where satellite cells are also present in high numbers (24) , may reflect that function.
An additional possibility that may underlie the elevated concentration of myostatin at MTJs is that this may reflect the elevated concentration of myostatin ligands at these sites. Proteins in the TGF-␤ superfamily are typically stored in an inactive form in the extracellular matrix (ECM) after their processing and secretion (25) . Release of these proteins from the ECM is thought to lead to their activation. For example, TGF-␤1 is bound in an inactive form to collagen IV and fibronectin and is activated upon release (19, 26, 27) . The interaction between TGF-␤1 and the ECM is mediated by LTBP (latent TGF-␤1 binding protein), which associates with the latent domain of TGF-␤1 via disulfide bonds and the ECM via other covalent interactions (19, 27) . The structural similarities between other TGF-␤ superfamily proteins and myostatin suggests that a similar regulatory mechanism may exist for myostatin. If myostatin binds the basement membrane in a manner similar to TGF-␤1, one would expect to see concentration of the protein at the MTJ due to folding of the basement membrane at this site. Additional studies in this area will contribute to understanding the regulation of myostatin activity.
The results of the current study support the hypothesis that myostatin plays a role in the loss of skeletal muscle mass due to unloading. However, previous investigations have provided data to show that other processes may also function in an important way in the loss of muscle mass. For example, Ca 2ϩ -dependent proteases, lysosomal proteases, and the ATP-ubiquitin-proteasome pathway can also contribute to proteolysis induced by muscle unloading. A period of 2-3 days of hind limb unloading is sufficient to induce an 8.5% loss in total protein concentration of soleus muscle that may be attributable to Ca 2ϩ -dependent proteases (28) . In addition, the concentration of lysosomal proteases increases during muscle unloading (29) , although it is reported that calpain concentrations may increase (29) or not change significantly during 10 days of unloading (30) . When soleus muscle is excised from a rat after 9 days of suspension and subsequently incubated with or without inhibitors of lysosomal and Ca 2ϩ -dependent proteases for 2 h, it appears that only 18% of the overall proteolysis observed can be attributed to lysosomal and Ca 2ϩ -dependent mechanisms (29) . This finding indicates that other mechanisms must be contributing to the majority of proteolysis and atrophy observed during muscle unloading. Although the significant increase in transcription of the proteasome subunits involved in the ATP-ubiquitin-proteasome pathway that occurs within 9 days of unloading suggests that the proteasome pathway may contribute to muscle mass loss, it has not been demonstrated that this increase in mRNA results in increased proteolysis in this model (29) .
The possibility that myostatin may modulate the expression or activity of proteases has not been examined, although this would provide a straightforward explanation for its proposed role in regulating muscle mass. This potential role in regulating the activity or expression of proteases would be consistent with known functions of TGF-␤, which can modulate the expression of proteases and their inhibitors (31, 32) . Alternatively, myostatin may play a broader role in regulating protein balance in muscle by exerting more general controls on translation or transcription, either directly or indirectly, through modulating the expression of growth factors. This latter possibility is also consistent with current knowledge of TGF-␤ functions (33) . Continuing studies are directed at identifying through which of these mechanisms myostatin may function in regulating muscle mass during unloading. This work was supported by a grant from the National Institutes of Health (AR40343). M.W. was supported by a Pauley Graduate Fellowship.
